Candel Therapeutics highlights $201.6 million in cash and cash equivalents as of June 30, 2026, with expected runway into 2028. Investors also get updated clinical and financing markers, including positive phase 3 prostate cancer data, positive survival results in two cancers, and facilities totaling up to $130 million and $100 million.

Key Highlights

  • Aglatimagene has been administered to more than 1,000 patients, with nearly 50% tumor-volume reduction reported in one NSCLC patient over three weeks.
  • Aglatimagene besadenovec (CAN-2409) is described as an off-the-shelf therapy for pan-solid tumors designed to generate an individualized anticancer immune response.
  • Linoserpaturev (CAN-3110) is an investigational oncolytic HSV-1 program designed for tumor-specific replication.
  • Candel reports positive overall survival data from phase 2a studies and expected cash runway into 2028.

Its September 2026 investor presentation highlights clinical progress for aglatimagene besadenovec and linoserpaturev, two programs designed to support cancer treatment development.

$130M Loan and $100M Royalty Agreement

Aglatimagene besadenovec, also known as CAN-2409, is described as an off-the-shelf therapy for pan-solid tumors that aims to generate an individualized anticancer immune response. The program has been administered to more than 1,000 patients and has received several regulatory designations across prostate cancer, non-small cell lung cancer and pancreatic cancer. Linoserpaturev, or CAN-3110, is an investigational oncolytic HSV-1 program designed for tumor-specific replication.

Clinical Data Supports 2028 Cash Runway

It also reports positive overall survival data from phase 2a studies in borderline resectable pancreatic cancer and therapy-resistant non-small cell lung cancer. A single non-small cell lung cancer patient treated with aglatimagene showed nearly 50% lower tumor Volume over three weeks. Candel (NASDAQ: CADL) also cites proof of concept for linoserpaturev in recurrent high-grade glioma, while its cash balance is described as providing expected runway into 2028.